1. Treatment Outcome of Combined Continuous Venovenous Hemofiltration and Hemoperfusion in Acute Paraquat Poisoning
- Author
-
Ya-Xiang Song, Wen Xue, Xinying Liu, Zhen Wang, Limin Zhao, Chandra Mohan, Zisheng Ai, Shu-Ling Fan, Dayong Hu, Xinhua Li, Jiafeng Cheng, Changbin Li, Liya Wang, and Ai Peng
- Subjects
Adult ,Male ,Paraquat ,Critical Care ,Hypophosphatemia ,medicine.medical_treatment ,Renal function ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cause of Death ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Hypoxia ,Adverse effect ,Prospective cohort study ,Gastric Lavage ,Cause of death ,business.industry ,Hazard ratio ,Acute kidney injury ,Acute Kidney Injury ,Hemoperfusion ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Thrombocytopenia ,Gastric lavage ,Treatment Outcome ,Anesthesia ,Female ,Hemofiltration ,business - Abstract
Objectives To investigate whether combined continuous venovenous hemofiltration and hemoperfusion among paraquat-poisoned patients would improve survival. Design Prospective, controlled interventional study over 4 years. Setting Single, tertiary, academic medical center. Patients We recruited patients admitted to Shanghai Tenth People's Hospital within 48 hours after paraquat ingestion. Exclusions were under 14 years old, ingestion of paraquat with other toxicants, pregnant, a history of chronic pulmonary disease, psychosis, hyperthyroidism, or diabetes with impaired liver or renal function. Interventions All patients were assigned to receive continuous venovenous hemofiltration with hemoperfusion therapy (continuous venovenous hemofiltration group) and to receive conventional therapy (conventional group). The study outcomes were death from any cause within 90 days after paraquat ingestion and the frequencies of hypoxia, acute kidney injury, or adverse events. Measurements and main results Of the 110 enrolled patients, 59 were assigned to continuous venovenous hemofiltration group and 51 to conventional group. The two groups had similar baseline demographics and clinical features. At 90 days after paraquat ingestion, 19 of 59 patients (32.2%) in the continuous venovenous hemofiltration group and 29 of 51 patients (56.9%) in the conventional group had died (hazard ratio, 0.43; 95% CI, 0.24-0.76; p = 0.004). In multivariable Cox proportional hazard models controlling for baseline characteristics, combined continuous venovenous hemofiltration and hemoperfusion was independently associated with reduced risk of death compared with conventional therapy (adjusted hazard ratio, 0.35; 95% CI, 0.19-0.64; p = 0.001). Patients in the continuous venovenous hemofiltration group, as compared to the conventional group, had a reduced occurrence rate of hypoxia (40.7% vs 72.5%; p = 0.001) and of acute kidney injury (59.3% vs 78.4%; p = 0.03). Hypophosphatemia and thrombocytopenia were more common in the continuous venovenous hemofiltration group (p Conclusions In patients with paraquat poisoning, treatment with combined continuous venovenous hemofiltration and hemoperfusion significantly improved 90-day survival rates.
- Published
- 2018
- Full Text
- View/download PDF